Acerus Pharmaceuticals Corporation
http://www.aceruspharma.com/English/home/default.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acerus Pharmaceuticals Corporation
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber
Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.
Pediatric Testosterone Therapy: Sponsors Wary Of Trials Despite PREA
Studies are unfeasible, sponsors argue in advance of US advisory committee meeting that could lead to FDA ending its waiver on requiring clinical trials in pediatric patients for new testosterone replacement therapy products.
Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Trimel BioPharma Holdings Inc.
- Trimel Biopharma SRL
- Trimel Pharmaceuticals Corporation